The treatment of acute lymphocytic leukemia.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use; D001792:Blood Platelets; D001854:Bone Marrow Cells; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004195:Disease Models, Animal; D004357:Drug Synergism; D006470:Hemorrhage / Q000150:complications; D006801:Humans; D007239:Infections; D007939:Leukemia L1210 / Q000473:pathology; D007945:Leukemia, Lymphoid / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D013921:Thrombocytopenia / Q000188:drug therapy; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin